美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Virtus LifeSci Biotech Products ETF

104.02

+0.56030.54%

成交量：8,735

成交額：90.96萬

市值：1.25億

市盈率：- -

高：104.62

開：103.72

低：103.29

收：103.46

52周最高：110.05

52周最低：68.05

股本：120.00萬

流通股本：120.00萬

量比：0.99

換手率：0.73%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業

特朗普：8月就業數據超預期，要求聯儲局降息

特朗普社媒动态

康寧傑瑞生物製藥回購56,000股耗資492,430港元

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

武漢友芝友生物製藥股份有限公司在香港暫停交易。

新股消息 | 貝達藥業(300558.SZ)再度遞表港交所「四駕馬車」協同打造全產業鏈生物製藥

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

海正藥業與星際開發達成戰略合作佈局太空生物製藥

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

阿巴斯生物製藥宣佈擬通過改良式「荷蘭拍賣」要約收購，回購最高價值2.3億美元的公司普通股。

駿利亨德森投資：專利到期倒逼藥企擴張生物科技併購、IPO市場同步復甦

智通财经网

杭蕭鋼構等投資成立生物製藥公司

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BBP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":104.02,"timestamp":1789415255831,"preClose":103.4597,"halted":0,"volume":8735,"delay":0,"changeRate":0.005415635266678698,"floatShares":1200004,"shares":1200004,"eps":0,"marketStatus":"交易中","change":0.5603,"latestTime":"09-14 15:52:23 EDT","open":103.72,"high":104.62,"low":103.285,"amount":909566.2909,"amplitude":0.012904,"askPrice":104.97,"askSize":600,"bidPrice":103.54,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":103.4597,"sharesOutstanding":600004,"nav":103.362,"aum":124035301.07,"bidAskSpread":0.00263,"preHourTrading":{"tag":"盘前","latestPrice":103.46,"preClose":103.4597,"latestTime":"07:00 EDT","volume":7,"amount":724.2199999999999,"timestamp":1789383610133,"change":0.0003,"changeRate":0.000003,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":103.45,"preClose":103.4597,"latestTime":"19:30 EDT","volume":7,"amount":724.2785,"timestamp":1789169406685,"change":-0.0097,"changeRate":-0.000094,"amplitude":0},"volumeRatio":0.994816,"impliedVol":0.2137,"impliedVolPercentile":0.2948},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1200004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.994816,"shares":1200004,"dividePrice":0,"high":104.62,"amplitude":0.012904,"preClose":103.4597,"low":103.285,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":104.02,"committee":-0.714286,"eps":0,"divideRate":0,"volume":8735,"delay":0,"ttmEps":0,"open":103.72,"prevYearClose":79.9149,"prevWeekClose":103.4597,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":108.3272,"twentyDayClose":101.3121,"sixtyDayClose":89.4018},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["RSPH","159839","PJP","BBP","APXH","BME","MEDI","TMED","PBPH","GSKH","IHE","BBH","IYH","PPH","TRUH","FXH","JDOC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665936888?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","HK0000165453.HKD","AGIX","MRNX","BK1191","HK0000320264.USD","AIPO","03069","HK0000306685.HKD","02696","MRNY","BK1574","01477","VTHR","HK0000320223.HKD","ARTY","QTOC","HK0000306701.USD","BK1161","CHAT","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132454908","title":"特朗普：8月就業數據超預期，要求聯儲局降息","url":"https://stock-news.laohu8.com/highlight/detail?id=1132454908","media":"特朗普社媒动态","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132454908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 21:41","pubTimestamp":1788529306,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANEW",".IXIC","LRCY","PEVC","CAOS","UCC","TSLP","BBP","IJK","FXL","RJZ",".SPX","CGDV",".DJI","VAW","DFUV","KOMP","AVSD","CLIX","FXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337721","title":"康寧傑瑞生物製藥回購56,000股 耗資492,430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337721","media":"财闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664337721?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:53","pubTimestamp":1788526380,"startTime":"0","endTime":"0","summary":"9月4日，康宁杰瑞生物制药于2026年9月4日在香港联交所回购56,000股普通股，每股回购价格最高HKD8.8、最低HKD8.75，付出价格总额HKD492,430。回购股份拟持作库存股份，拟注销数目为0。回购后，已发行股份数目由968,056,697股减至968,000,697股，库存股份数目由6,325,000股增至6,381,000股，已发行股份总数维持974,381,697股。此次回购依据2026年6月12日获通过的回购授权进行，该授权可回购股份总数为96,850,669股。回购后暂止期截至2026年10月4日。呈交者为执行董事徐霆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqsrak4001786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","03069","CNAV","MRNY","BBP","EWH","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BBP","MEDX","RSPH","IBB","GNOM","WDNA","IE00BFTCPJ56.SGD","MRNX","PBPH","PSCH","IBRN","IE00B4R5TH58.HKD","IYH","BK4588","SYNB","BIB","PPH","LU2322448957.HKD","RXL","IEHS","PBE","HELX","SBIO","AZNH","BK4585","IE0009355771.USD","LFSC","MRNY","LU2473716301.USD","IE0002141913.USD","NVS","BBH","FTXH","LU2272731600.USD","IE00BJT1NW94.SGD","XPH","MEDI","CANC","FBT","LU0211331839.USD","XBIX","BIOY","LU0070302665.USD","TMED","PJP","IEIH","IE00BJJMRZ35.SGD","IDNA","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","QTOC","BIOY","AGIX","GDOC","IPOS","LFSC","WRND","GSKH","APXH","BBP","BK4585","SBIO","IBB","XLVI","ARTY","AIPO","PBE","VTHR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663238000","title":"武漢友芝友生物製藥股份有限公司在香港暫停交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2663238000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663238000?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 08:36","pubTimestamp":1788136595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MRNY","BBP","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663302804","title":"新股消息 | 貝達藥業(300558.SZ)再度遞表港交所 「四駕馬車」協同打造全產業鏈生物製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2663302804","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663302804?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 08:14","pubTimestamp":1788135285,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月28日披露，贝达药业股份有限公司向港交所主板提交上市申请，中信证券为其独家保荐人。毛利率于2023年度、2024年度、2025年度及2026年截至6月30日止六个月，公司对应毛利率分别为82.7%、80.5%、78.3%、75.1%。全球及中国的肺癌发病率和死亡率均呈上升趋势。全球肺癌新发病例数从2020 年的230万增至2025年的270万，预计到2035年将增至350万。目前，FDA已批准6种ALK TKI上市，EMA已批准5种ALK TKI上市，国家药监局已批准10种ALK TKI上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","MRNY","IPOS","BBP","BK0060","HEXmain","300558","MRNX","IBBQ","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WRND","GSKH","PBE","BK4588","LFSC","BBP","SBIO","BIOY","APXH","XLVI","BK4585","GDOC","IBB","BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662058121","title":"海正藥業與星際開發達成戰略合作 佈局太空生物製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2662058121","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662058121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 10:52","pubTimestamp":1787885542,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNY","IBBQ","MRNX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","GDOC","XLVI","BK4585","BK0216","SBIO","159399","IBB","BK4588","GSKH","SPHQ","APXH","WRND","300404","LFSC","PBE","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661672552","title":"阿巴斯生物製藥宣佈擬通過改良式「荷蘭拍賣」要約收購，回購最高價值2.3億美元的公司普通股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661672552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661672552?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 19:30","pubTimestamp":1787311853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","EVNT","MRNY","MRNX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431564","title":"駿利亨德森投資：專利到期倒逼藥企擴張 生物科技併購、IPO市場同步復甦","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431564","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:06","pubTimestamp":1787126785,"startTime":"0","endTime":"0","summary":"骏利亨德森投资称，尽管利率较市场年初的预期为高，但生物科技行业交易活动的增长动力持续不减。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","IWO","JDOC","MRNY","BIS","IBB","SPCK","FBT","MRNX","IJT","BK4588","BIB","PBE","BK4582","GTPE","BBP","IBBJ","IYG","BBC","QSML","IAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660415061","title":"杭蕭鋼構等投資成立生物製藥公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660415061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660415061?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:44","pubTimestamp":1787103899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","IBBQ","MRNY","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601881","BK0276","BK1147","06881","BIOY","GDOC","LFSC","WRND","GSKH","BK0188","APXH","BBP","BK4585","SBIO","IBB","XLVI","BK1564","161027","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","PBE","GSKH","LFSC","BK0102","GDOC","600721","BK4585","BK4588","BK0216","SBIO","WRND","APXH","IBB","BIOY","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC","WRND","BBP","APXH","BK4588","BIOY","GDOC","GSKH","SBIO","PBE","IBB","XLVI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WRND","SBIO","LFSC","PBE","APXH","BK0102","BK0216","GDOC","BIOY","BK4585","BBP","GSKH","XLVI","IBB","BK4588","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK4588","AIPO","LFSC","BK1147","IBB","BIOY","BK4585","SBIO","BK0012","BK0028","BK1564","BK0188","BK0183","CHAT","PBE","WRND","ARTY","APXH","600958","QTOC","03958","BBP","BK0276","XLVI","VTHR","GSKH","AGIX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}